
It was founded in 1952 by Ramanbhai Patel. It is only Indian pharmaceutical company to have 18+ experience in biosimilars. It also has a consumer healthcare subsidiary Zydus Wellness.
Cadila Healthcare Product Segments
Speciality Generics
Biosimilars
Vaccines
- New Chemical Entities
- Consumer Health
Revenue from various markets
Therapeutic area-wise sales breakup in India
Research division for novel drug discovery with focus areas of Pain, Cancer, Inflammation, Infection, Cardio-metabolic. Lipaglyn the novel drug to treat diabetic dyslipidemia is the first NCE from Indian research pipeline to move to market. Currently, there are 10+ drugs in NCE pipeline.
Biosimilars
Biosimilars are officially approved versions of original "innovator" biotech products and can be manufactured after original product's patent expires. It is No.1 player in biosimilar space and has portfolio of 11 commercial biosimilars in Indian market. Exemptia is world’s first biosimilar of Adalimumab which is a drug for inflammatory arthritis.
Vaccines
Zydus has been developing vaccines for Diphtheria, Pertussis, Tetanus, Haemophilus Influenzae type B, Hepatitis B, Measles, Mumps, Rubella, Varicella, Influenza and Typhoid fever. Zydus has launched India's first Tetravalent Inactivated Influenza vaccine, VaxiFlu – 4. (treats H1N1, H3N2, Type B (Brisbane), Type B (Phuket) )
Speciality & Complex Generics
Zydus provides speciality generics in areas of Pain Management, Dermatology, Speciality Oncology, Speciality Neurology, Gastroenterology, Liver Diseases and Rare diseases.
Consumer HealthcareZydus Wellness is a subsidiary that handles the consumer healthcare segment and contributes ~12% revenue. SugarFree, Nycil, Complan, Everyuth, Glucon-D, Nutralite & Heinz Ketchup are flagship products.


Cadila Healthcare Subsidiaries
- Zydus Wellness
- Windlas Healthcare
- Bayer Zydus Pharma
- Takeda Pharmaceuticals
Comments
Post a Comment